Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and doxorubicin adjuvant chemotherapy strategies for node-positive breast cancer
ACTRN12606000529549Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jun 1998
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel, doxorubicin, cyclophosphamide, methotrexate and fluorouracil in breast cancer (4 arms), sponsored by Sanofi. Primary endpoint: Disease-free survival: docetaxel-containing regimens versus non-docetaxel regimens. Started Jun 1998; status: completed.
02
Drugs
docetaxeldoxorubicincyclophosphamidemethotrexatefluorouracil
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000529549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000529549.